Precision BioSciences (NASDAQ:DTIL) Announces Quarterly Earnings Results

Precision BioSciences (NASDAQ:DTIL) issued its quarterly earnings results on Thursday. The company reported ($1.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.46), FiscalAI reports. Precision BioSciences had a negative return on equity of 67.70% and a negative net margin of 96.73%.

Precision BioSciences Stock Up 0.9%

Shares of DTIL stock traded up $0.07 on Friday, reaching $7.49. 240,103 shares of the stock were exchanged, compared to its average volume of 341,234. The company has a current ratio of 14.02, a quick ratio of 14.02 and a debt-to-equity ratio of 0.29. The business’s 50 day moving average price is $7.36 and its 200 day moving average price is $6.33. The company has a market capitalization of $193.24 million, a price-to-earnings ratio of -2.67 and a beta of 1.27. Precision BioSciences has a twelve month low of $3.53 and a twelve month high of $9.62.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the stock. JonesTrading reaffirmed a “buy” rating and set a $30.00 target price on shares of Precision BioSciences in a research note on Friday, April 17th. HC Wainwright restated a “buy” rating on shares of Precision BioSciences in a research note on Monday, August 3rd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Precision BioSciences in a research report on Wednesday. Wall Street Zen cut Precision BioSciences from a “hold” rating to a “sell” rating in a research note on Saturday. Finally, Oppenheimer began coverage on Precision BioSciences in a research note on Tuesday, June 9th. They set an “outperform” rating and a $20.00 target price for the company. Four equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, Precision BioSciences presently has a consensus rating of “Moderate Buy” and an average target price of $32.25.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the business. Engineers Gate Manager LP purchased a new stake in Precision BioSciences during the fourth quarter worth approximately $43,000. Occudo Quantitative Strategies LP acquired a new stake in Precision BioSciences during the fourth quarter worth approximately $52,000. Virtu Financial LLC purchased a new stake in shares of Precision BioSciences during the 3rd quarter worth approximately $84,000. Velan Capital Investment Management LP acquired a new position in shares of Precision BioSciences in the 3rd quarter valued at $110,000. Finally, Citadel Advisors LLC purchased a new position in shares of Precision BioSciences during the third quarter worth about $122,000. 37.99% of the stock is owned by institutional investors and hedge funds.

Precision BioSciences Company Profile

Precision BioSciences is a clinical?stage genome editing company that leverages its proprietary ARCUS platform to develop targeted gene therapies. ARCUS, an engineered nuclease derived from a naturally occurring enzyme, enables precise DNA modifications for both in vivo and ex vivo applications. The company’s pipeline spans genetic diseases—including rare monogenic disorders—and immuno?oncology, where it is advancing allogeneic cell therapy candidates designed to address hematologic malignancies and solid tumors.

Founded in 2006 as a spin?out from research at the University of North Carolina, Precision BioSciences is headquartered in Durham, North Carolina, with additional research and manufacturing capabilities located in the Research Triangle Park area.